Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 10744 matches for

Today a new drug will become available for patients with bowel cancer as part of a national clinical trial; based on a scientific discovery made only two years ago at the University of Oxford.

© Humphrey Lab
SETD2-deficient kidney cancer cells, courtesy of Humphrey group, Department of Oncology, University of Oxford
Jie Yang

Jie Yang

BVetMed, PhD Jie Yang - Group Leader - T cell immunity and immunosuppression in cancer

Matthew Jackson

Matthew Jackson

DPhil, BSc (Hons) Matthew Jackson - Postdoctoral research scientist

Giulia Orlando

Giulia Orlando

MSc, DPhil Giulia Orlando - Group Leader - Epigenetic Reprogramming in Cancer

Shazia Irshad

Shazia Irshad

PhD Shazia Irshad - Senior Research Associate

Lucy Brooks

Lucy Brooks

MSci, PhD Lucy Brooks - Group Leader

Hala Estephan

Hala Estephan

PhD Hala Estephan - Postdoctoral Researcher

Yang-Hong Dai

Yang-Hong Dai

MD Yang-Hong Dai - DPhil student

Dimitris Vavoulis

Dimitris Vavoulis

BSc, MRes, MSc, PhD Dimitris Vavoulis - Computational Biologist

Juliet Lawrence

Juliet Lawrence

Juliet Lawrence - Communications Officer

Aihan Zhang

Aihan Zhang

BSc, PhD Aihan Zhang - Postdoctoral researcher

Qiwen Huang

Qiwen Huang

B.S., M.S. Qiwen Huang - DPhil Student

Peter Wan

Peter Wan

BSc, MPhil, DPhil Peter Wan - Postdoctoral researcher

Olivier Zanier

Olivier Zanier

MMed Olivier Zanier - DPhil student

Ahmet Hazini

Ahmet Hazini

PhD Ahmet Hazini - PCUK Career Acceleration Fellow

Tess Stanly

Tess Stanly

Dphil Tess Stanly - Postdoctoral Research Scientist

Mark Macsuka

Mark Macsuka

MSci Mark Macsuka - DPhil student

Shannon Russell

Shannon Russell

Sandeep Unwith

Sandeep Unwith

Sandeep Unwith - DPhil Student

Rebecca Brehm

Rebecca Brehm

MSc Clinical Trials, BSc (Hons) Biological Sciences Rebecca Brehm - Clinical Trial Administrator - Oncology Clinical Trials Office (OCTO)

Anastasia Kosmidou

Anastasia Kosmidou

Anastasia Kosmidou - MRes Student

Load More

Similar stories

Oxford Cancer launches 2025 OCION Funding Scheme

The 2025 Oxford Cancer Immuno-Oncology Network (OCION) Funding Scheme is now open!

New Study Finds Common Virus May Improve Skin Cancer Treatment Outcomes

A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.

Oxford and GSK launch £50million immuno-prevention programme to advance novel cancer research

Global biopharma company GSK invests up to £50 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.

Machine Learning Enhances Detection of Multiple Cancer Types from Blood

Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test’s potential to transform early cancer detection and improve patient outcomes.

Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer

The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper “Goblet Cell Differentiation Subgroups in Colorectal Cancer.” This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.

Ground-breaking Study reveals previously unknown genetic causes of Colorectal Cancer

A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).